Liquid biopsy: from discovery to clinical application
C Alix-Panabières, K Pantel - Cancer discovery, 2021 - AACR
Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …
have received enormous attention as new biomarkers and subjects of translational research …
Liquid biopsy enters the clinic—implementation issues and future challenges
M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
Epigenetic mechanisms in breast cancer therapy and resistance
L Garcia-Martinez, Y Zhang, Y Nakata, HL Chan… - Nature …, 2021 - nature.com
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this
pathway represent the main treatment modality. Endocrine therapy has proven successful in …
pathway represent the main treatment modality. Endocrine therapy has proven successful in …
A view on drug resistance in cancer
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …
approach to define and separate the key determinants of drug resistance, which include …
Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)
Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …
biomarker for early detection of molecular residual disease (MRD) and prediction of …
Liquid biopsy and minimal residual disease—latest advances and implications for cure
K Pantel, C Alix-Panabières - Nature Reviews Clinical Oncology, 2019 - nature.com
Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …
of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free …